Clinical Trial Update: Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) [Phase 2]

View source ↗

Summary

Phase 2 trial (PACE-LUNG) evaluating additional chemotherapy in EGFR mutation-positive non-small cell lung cancer patients who have persistent plasma EGFRm ctDN…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Goethe University | Conditions: NSCLC Stage IIIB, NSCLC Stage IV | Phase 2 | Status: RECRUITING